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Seniors are heavy users of medications. Despite strong
evidence that some medications are associated with an
increased risk of serious adverse consequences in seniors,
physicians prescribe, pharmacists dispense, plans pay and
seniors suffer. One such adverse consequence is a fall 
secondary to dizziness or instability of gait. A fall with a
resulting fracture is a leading cause of hospitalizations
and deaths of seniors.
OBJECTIVES: To advance the quality of its prescription
drug beneﬁt, a telecommunications company studied
whether taking prescription drugs both known or 
suspected of causing dizziness or instability of gait in
seniors increase the likelihood of fractures. The pre-
scription drugs studied included: propoxyphene and com-
binations; hydantoin anticonvulsants; benzodiazepines;
selective serotonin reuptake inhibitors; and tricyclic 
antidepressants.
METHODS: This analysis studied the rate of hip frac-
tures in a group of 35,264 members over a ﬁve-year
period from 1996 to 2000. Each member in the study
reached the age of 65 by January 1, 1996. Parametric
duration regression models were used to quantify the
impact of taking certain prescription drugs on the likeli-
hood of subsequently having a hip fracture and to control
for differences between study members with hip fractures
and those without.
RESULTS: Nearly 4% of the study population experi-
enced a hip fracture during the time period. Each addi-
tional year of age increased the likelihood of having a hip
fracture by 10.5%. Females were 73 percent more likely
than males to have a hip fracture. Members who took
amitriptyline were 48 percent more likely, and members
who took temazepam were 27 percent more likely to have
a subsequent hip fracture during the study period.
CONCLUSIONS: Amitriptyline and temazepam in-
creased the likelihood of hip fracture among Medicare-
eligible plan members. The telecommunications company
will use this evidence to reduce the use of these medica-
tions, when appropriate, by its members.
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GENERIC NARROW THERAPEUTIC INDEX
DRUG USE: 1996–1998
Chao J,Taylor SD, McKercher PL, Kirking DM
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The FDA has designated 23 pharmaceutical entities as
Narrow Therapeutic Index (NTI) drugs based on the
range between therapeutic and toxic dose levels. The
generic substitution of NTI drugs has been controversial
due to perceived bioequivalence problems.
OBJECTIVES: We examined the ambulatory generic 
NTI drug use and cost from 1996 through 1998 and com-
pared NTI drugs with non-NTI drugs in generic use. The
relationship between generic use and retail pricing was
explored.
METHODS: This study examined secondary data 
using 1996–1998 Medical Expenditure Panel Survey
(MEPS) data. MEPS provides nationally representative
estimates of health care use, expenditures, sources of
payment, and insurance coverage for the U.S. civilian
non-institutionalized population.
RESULTS: NTI drugs represent 7.0%, 6.3%, and 5.9%
of total annual prescriptions from 1996 to 1998, respec-
tively, which correspond to 6.1%, 5.2%, and 4.9% of
total prescription expenditures. Among multiple-sources
drugs, NTI drugs are more likely than non-NTI drugs to
be dispensed by brandname with odds ratios of 3.9, 3.4,
and 4.1 in 1996, 1997, and 1998, respectively (P < 0.05).
The median discount rates for non-NTI drugs are 0.35
and 0.32 for 1996 and 1997 compared to rates of 0.36
and 0.34 for NTI drugs. Accordingly, the realized savings
from generic NTI drugs were 249.2 and 265.3 million
dollars for 1996 and 1997. If NTI drugs had the same
generic use rates as non-NTI drugs, an additional 293.6
and 147.7 million dollars could have been saved. The dis-
count rates of generic drugs were positively associated
with use in both NTI and non-NTI drugs in 1996 with a
stronger effect in NTI drugs. The switch rates of NTI
drugs were not different from those of non-NTI drugs.
CONCLUSIONS: Generic NTI drugs were used at a
lower rate than non-NTI drugs from 1996 to 1998.
Increased generic NTI drugs use could lead to more
savings.
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OBJECTIVE: To examine the impact of two and three-
tiered prescription drug beneﬁts on medication adherence
rates among managed care patients with selected chronic
conditions.
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METHODS: Quasi-experimental, pre-post with compar-
ison groups design using 6109 adult patients in a large,
western U.S. managed care organization with one or more
of the following conditions: arthritis, diabetes, dyslipi-
demia, GERD, or hypertension. The intervention group
consisted of members whose prescription drug coverage
converted from a 2-tier to a 3-tier beneﬁt (n = 4239).
Comparison groups included those whose beneﬁts
remained in a 2-tier (n = 592) or 3-tier (n = 1278) struc-
ture. Medication adherence rates were measured in the
pre and post periods using the medication possession
ratio. Demographic and attitudinal measures were
obtained from a mail survey during the pre period. 
Statistical analyses were based on maximum likelihood
estimates from a repeated measures model to test for dif-
ferences in medication adherence controlling for the
effects of demographic variables, health status, comorbid
diseases, pharmacy plan type, and patient satisfaction.
RESULTS: Adherence rates ranged from 90.4% to 95.5%
in the pre period. The mean adherence rate in the 
intervention group decreased from 94.7% (pre period) 
to 90.2% (post period), a decrease of 4.5%. Similar
decreases occurred in the comparison groups: from
95.5% to 91.7% (-3.8%) for 2-tier subjects, and from
92.9% to 90.4% (-2.5%) for 3-tier subjects. The
decrease in the intervention group was signiﬁcantly larger
than the decrease in the 3-tier subjects (p = 0.0003) but
not statistically different from the decrease observed in
the 2-tier subjects (p = 0.27). Adherence increased slightly
as age and number of chronic conditions increased. No
relationship was observed between medication adherence
and patient satisfaction (p = 0.35 in the pre period).
CONCLUSION: Medication adherence rates were high
in the population studied. Changes in beneﬁt design (from
2 to 3-tier drug beneﬁts) had no appreciable impact on
adherence.
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OBJECTIVES: This study measured prescription drug
utilization and payment changes when Texas Medicaid
clients in one County Service Area moved from a fee-for-
service (FFS) to either a health maintenance organization
(HMO) or primary care case management (PCCM) health
care delivery model (N = 72,172). The purpose of this
study was to assess the effect that the managed care 
programs had on the prescription drug utilization of
Medicaid clients who had a carved-out prescription 
drug beneﬁt.
METHODS: Drug utilization and payment patterns were
compared for six-month periods before and after the
managed care program implementation. Medicaid clients
in FFS, HMO, and PCCM programs in three other geo-
graphical areas across the state served as comparison
groups (N = 54,061).
RESULTS: Signiﬁcant differences (p < 0.001) across plan
designs were found in the mean changes of the following
variables between study periods for child and adult
clients: 1) prescription drug use rates; 2) generic drug 
use; 3) prescription drug payments per claim; and 4) pre-
scription drug payments per client. Furthermore, these
changes were found to be signiﬁcantly different across
plan designs for child and adult antibiotic claims, and for
child antidepressant claims. Signiﬁcant differences were
found for the following variables for child and adult anti-
histamine claims, and for child NSAID claims: 1) generic
drug use; 2) prescription drug payments per claim; and
3) prescription drug payments per client. For adult anti-
depressant and NSAID claims, signiﬁcant differences
were found in the following variables: 1) prescription
drug use rates; 2) generic drug use; and 3) prescription
drug payments per client.
CONCLUSION: This study provided evidence of a
managed care spillover effect on the prescription drug 
utilization of Medicaid managed care patients, despite the
carved-out drug beneﬁt. The results of this study should
be helpful to Medicaid administrators who make deci-
sions about managed care programs and carved-out drug
beneﬁts.
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OBJECTIVE: International comparisons of horizontal
inequity in health have recently become one of the most
pertinent issues in health economics. Japan has not been
included in these international comparisons. This paper,
focusing on Japan, rectiﬁes this and considers its dynam-
ics over six years from 1992 to 1998, which has never
been considered in this ﬁeld.
METHODS: We use the Comprehensive Survey of Living
Standards in Japan (CSLSJ) for 1992, 1995, and 1998 
so as to perform international comparison following
Doorslaer and Wagstaff et al (JHE:2000). The sample 
size for each year exceeds 60,000. First of all, we regress
outpatient utilization on age, gender, self-evaluation of
health, and/or list of symptoms and deﬁne “Needs” as the
predicted. Then, Kakuwani index between actual utiliza-
tion and “Needs” is calculated.
RESULTS: In a rigorous international comparison, we
cannot ﬁnd any horizontal inequity in health in Japan.
The point estimator is larger than Belgium and less than
Canada, which means the smallest horizontal inequity 
in OECD countries. Moreover, it gradually changes 
from pro-rich to pro-poor, though this movement is not
signiﬁcant.
